ImmunoPrecise to Acquire QVQ Holdings BV and Reports Growth Results

ImmunoPrecise (TSXV:IPA) has announced it has signed a binding letter of intent with QVQ Holdings whereby Immuno will acquire all of the issued and outstanding shares of QVQ.
As quoted in the press release:

Currently, U-Protein Express B.V., a wholly owned subsidiary of the Company owns 37% of the issued and outstanding shares of QVQ.

The addition of QVQ will broaden the portfolio of research services the Company can offer its customers.  Additionally, QVQ has an available inventory of both unique and/or patented monoclonal antibodies that are being sold directly to customers.
QVQ
QVQ is a privately held company based in Utrecht, The Netherlands that performs Contract Research for pharmaceutical, biotech and diagnostic companies. A second area of focus for QVQ is working with Universities and research institutes in Collaboration Agreements to develop new intellectual property in the area of diagnostic imaging products.
QVQ’s core capability is the production of single domain antibodies, which are referred to as VHHs. These single-domain monoclonal antibodies are derived from llamas and other camelids. Due to their small size, they have unique biochemical properties ideal for applications in fast-growing areas such as tumor targeting, companion diagnostics, antibody fragments, and bi-specific antibodies, which drug developers are increasingly interested in applying to disease targets in many areas like oncology, diseases of aging, and infectious diseases.  Another benefit of  VHH molecules is that they are easily humanized due to their similarity to key regions of human antibodies.  QVQ has the capability to humanize these antibodies when they are used for therapeutic applications.

Click here to read the full press release.